Renal cell carcinoma (RCC) is a significant cause of death, particularly in the elderly, and makes accounting for about 3% of all cancer cases. In kidney cancer, as in many other malignancies, treatment response and strategy are largely dependent on the prognosis at the time of diagnosis. Targeted therapies have been the subject of many studies in kidney cancer treatment in recent years. We looked into the objective response rate (ORR), overall survival (OS), progression-free survival (PFS), treatment options, adverse effects, and demographics of patients with kidney cancer in our study. Patients having a diagnosis of kidney cancer were included in the study, received tyrosine kinase inhibitor treatment, and were treated and followed up in our center between January 2005 and September 2017 at the Medical Oncology Clinic of Internal Medicine, Faculty of Medicine, Ondokuz Mayıs University. The files of these patients were analyzed retrospectively. 160 RCC patients in all who had treatment and followed up in our center were evaluated. The study included 62 patients who received tyrosine kinase inhibitors after first-line interferon in the metastatic period. The age range was 24-79 years old 24 to 79 years, with a median age of 62.7 years at the time of diagnosis. Forty-four (70.9%) patients were treated with sunitinib and 18 (29.1%) patients were treated with pazopanib in the first-line setting after metastatic interferon. PFS was 10.8 months for pazopanib and 11.4 months for sunitinib. OS was 23.6 months with for pazopanib and 25 months with for sunitinib therapy. ORR was 19% with sunitinib. Anemia was the most common hematologic adverse effect and fatigue was the most frequent non-hematologic side effect after sunitinib treatment, according to evaluations of side effects both hematological and non-hematological. according to evaluations of both hematological and non-hematological side effects. Individuals treated with sunitinib with pazopanib exhibited prolonged progression-free survival and overall survival. The results suggest that created treatments for m-RCC are successful.
overall survival kidney cell cancer tyrosine kinase inhibitors
Ondokuz Mayıs University Ethics Committee/Approval Date-No: December 15, 2017- B.30.2.ODM.0.20.08/1258.
No
Birincil Dil | İngilizce |
---|---|
Konular | Klinik Onkoloji |
Bölüm | Research Article |
Yazarlar | |
Yayımlanma Tarihi | 19 Mayıs 2024 |
Gönderilme Tarihi | 29 Aralık 2023 |
Kabul Tarihi | 2 Nisan 2024 |
Yayımlandığı Sayı | Yıl 2024 Cilt: 41 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.